Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant treatment in gastric cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Despite recent advances in the treatment of gastric cancer, mortality related to this disease is still substantial. Surgery and chemotherapy represent the cornerstones of patient management. Targeted treatments that include anti-angiogenic agents and the advent of immunotherapies can contribute to improved patient prognosis. Herein, we present an Austrian consensus on the systemic treatment of patients with gastric adenocarcinoma and lower gastroesophageal junction, including those with human epidermal growth factor receptor 2 (HER2)-positive disease. The consensus considers the curative setting, as well as first-line to late-line systemic treatment options in the palliative setting. For HER2-positive disease, first-line and second-line therapies are discussed, as well as HER2 testing. Potential future therapies are also listed, with a focus on anti-angiogenic treatments and checkpoint inhibition, which might provide a further step forward in the management of patients with gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Noone AM, Howlader N, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, USA. 2015. http://seer.cancer.gov/csr/1975_2013/ (Created 11.2015), SEER datasubmission, posted to the SEER web site, April 2016.

  2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.

    Article  CAS  PubMed  Google Scholar 

  3. FLOT4-AIO Investigators, Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.

    Article  Google Scholar 

  4. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. https://doi.org/10.1093/annonc/mdw350.

    Article  CAS  PubMed  Google Scholar 

  5. Wöll E, Eisterer W, Gerger A, Kühr T, Prager GW, Rumpold H, et al. Treatment algorithm for patients with gastric adenocarcinoma: an Austrian consensus on systemic therapy. Anticancer Res. 2019;39(9):4589–96. https://doi.org/10.21873/anticanres.13638.

    Article  CAS  PubMed  Google Scholar 

  6. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708. https://doi.org/10.1016/S1470-2045(16)30531-9.

    Article  CAS  PubMed  Google Scholar 

  7. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric Infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197–203. https://doi.org/10.1001/jamaoncol.2016.6762.

    Article  PubMed  Google Scholar 

  8. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. https://doi.org/10.1200/JCO.2010.33.0597.

    Article  CAS  PubMed  Google Scholar 

  9. GO2 Trial Investigators, Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced Gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. 2021;7(6):869–77. https://doi.org/10.1001/jamaoncol.2021.0848. Erratum in: JAMA Oncol. 2021 Aug 1;7(8):1249.

    Article  Google Scholar 

  10. Vermillion SA, Hsu FC, Dorrell RD, Shen P, Clark CJ. Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients. J Surg Oncol. 2017;115(8):997–1003. https://doi.org/10.1002/jso.24617.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304. https://doi.org/10.1200/JCO.18.01138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. ARTIST 2 investigators, Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S‑1 with oxaliplatin, and postoperative chemoradiation with S‑1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32(3):368–74. https://doi.org/10.1016/j.annonc.2020.11.017.

    Article  CAS  Google Scholar 

  13. CRITICS investigators, Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28. https://doi.org/10.1016/S1470-2045(18)30132-3.

    Article  Google Scholar 

  14. Cats A, Sikorska K, Verheij M. Adjuvant therapy in resectable gastric cancer-the CRITICS trial—Authors’ reply. Lancet Oncol. 2018;19(7):e331. https://doi.org/10.1016/S1470-2045(18)30436-4.

    Article  PubMed  Google Scholar 

  15. Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. Bmc Cancer. 2018;18(1):877. https://doi.org/10.1186/s12885-018-4770-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6. https://doi.org/10.1200/JCO.2014.58.3930.

    Article  CAS  PubMed  Google Scholar 

  17. CROSS Group, Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. https://doi.org/10.1056/NEJMoa1112088.

    Article  Google Scholar 

  18. Anderson E, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, et al. A comparison of clinicopathologic outcomes across neoadjuvant and adjuvant treatment modalities in resectable gastric cancer. JAMA Netw Open. 2021;4(12):e2138432. https://doi.org/10.1001/jamanetworkopen.2021.38432.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.

    Article  CAS  Google Scholar 

  20. Rivera F, Izquierdo-Manuel M, García-Alfonso P, Martínez de Castro E, Gallego J, Limón ML, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158–67. https://doi.org/10.1016/j.ejca .2020.12.005.

    Article  CAS  Google Scholar 

  21. Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5‑fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‑positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322–31. https://doi.org/10.1002/ijc.33696.

    Article  CAS  PubMed  Google Scholar 

  22. Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, et al. Perioperative treatment in resectable gastric cancer: current perspectives and future directions. Cancers. 2019;11(3):399. https://doi.org/10.3390/cancers11030399.

    Article  CAS  PubMed Central  Google Scholar 

  23. Hofheinz R, Haag G, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol. 2020;38:4502–4502.

    Article  Google Scholar 

  24. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–84.

    Article  CAS  Google Scholar 

  25. Wagner AD. NCT02205047—neoadjuvant study using trastuzumab or trastuzumab with pertuzumab in gastric or gastroesophageal junction adenocarcinoma (INNOVATION). ClinicalTrials.gov 2016.. https://clinicaltrials.gov/ct2/show/NCT02205047. Accessed 11 May 2022.

  26. Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, et al. KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019;15(9):943–52. https://doi.org/10.2217/fon-2018-0581.

    Article  CAS  PubMed  Google Scholar 

  27. Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, et al. VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study. Front Oncol. 2020;9:1320. https://doi.org/10.3389/fonc.2019.01320.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Al-Batran SE, Pauligk C, Hofheinz R, Lorenzen S, Wicki A, Siebenhuener AR, et al. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esphagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. J Clin Oncol. 2019;37(15_suppl):TPS4142–TPS4142.

    Article  Google Scholar 

  29. Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, et al. Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment. Bull Cancer. 2020;107(4):438–46. https://doi.org/10.1016/j.bulcan.2019.11.016. French.

    Article  PubMed  Google Scholar 

  30. Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol. 2017;18(3):357–70. https://doi.org/10.1016/S1470-2045(17)30043-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76. https://doi.org/10.1200/JCO.2011.36.2236.

    Article  CAS  PubMed  Google Scholar 

  32. REGARD Trial Investigators, Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. https://doi.org/10.1016/S0140-6736(13)61719-5.

    Article  CAS  Google Scholar 

  33. RAINBOW Study Group, Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.

    Article  CAS  Google Scholar 

  34. Al-Batran SE, Bankstahl US. NCT02661971—perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma—RAMSES—a phase II/III trial of the AIO. ClinicalTrials.gov. 2017.

    Google Scholar 

  35. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79. https://doi.org/10.3322/caac.21657.

    Article  PubMed  Google Scholar 

  36. Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609–19. https://doi.org/10.1016/j.annonc.2021.02.005.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Vinzenz Hospital Zams, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511, Zams, Austria

    Bettina Sonnweber, Marc Schaber & Ewald Wöll MD

Authors
  1. Bettina Sonnweber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Schaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewald Wöll MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewald Wöll MD.

Ethics declarations

Conflict of interest

B. Sonnweber, M. Schaber and E. Wöll declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sonnweber, B., Schaber, M. & Wöll, E. Neoadjuvant treatment in gastric cancer. memo 15, 211–215 (2022). https://doi.org/10.1007/s12254-022-00823-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00823-8

Keywords

Search

Navigation